Please visit our MS learning channel on YouTube, which provides hundreds of MS related topics from many of our video recorded education programs and archived here: www.youtube.com/msviewsandnews -- Be empowered with MS views and news. Opt-in with us: www.register.msviewsandnews.org


~~ Scroll left side of this blog for needed resources. Also, use our 'search by topic' tool, to find specific information.


Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.

=================================================


Monday, July 30, 2018

• African-Americans Show Better Adherence and Satisfaction with Gilenya Than Injectable DMTs, Phase 4 Study Finds

JULY 30, 2018    by:  Jose Marques Lopes, PhD

Gilenya and treatment retention

African-Americans with relapsing–remitting multiple sclerosis (RRMS) show higher adherence and greater satisfaction when treated with oral Gilenya (fingolimod, by Novartis) than with injectable therapies, according to a new study.
Although the efficacy and safety of injectable disease-modifying therapies (iDMTs) used as first-line treatments for relapsing forms of MS are well-established, patients are also known from real-world studies to often discontinue using them and become non-adherent to these therapies. Research has shown that poor treatment retention, which includes adherence to and persistence in use over the long term, is key for better outcomes in MS.
To optimize treatment, clinicians need information on the efficacy, safety, tolerability, and convenience of therapies in specific patient groups.
Studies show that African-American MS patients can have a more aggressive disease course than Caucasians, including a greater likelihood of disability accumulation. Although not widely studied for MS, this patient population in diseases like hypertension, rheumatoid arthritis and asthma are known to have lower treatment retention rates than those of other patient groups.
The Phase 4 PREFERMS study (NCT01623596), sponsored by Novartis, randomized about 850 RRMS patients ages 8–65 to oral Gilenya or an injectable DMT. Its goal was  to better understand retention to treatment with Gilenya in specific populations. All enrolled had either never taken any iDMT previously or only one such medication; patients allowed one treatment switch after 12 weeks or earlier for safety or efficacy reasons.


No comments: